Skip to main content

HNSA · Hansa Biopharma AB · Financials

33.8400 SEK +0.6200 (+1.87%) At close · Oct 6
Market Cap
3.37B SEK
Shares
99.73M

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Browse captured authority reports and their original financial labels

Revenue
222.27M +29.7%
FY2025 Revenue FY2020–FY2025
Net Income
-534.11M +33.8%
FY2025 Net Income FY2020–FY2025
Gross Margin
62.41% +11.2pp
FY2025 Gross Margin FY2020–FY2025
Operating Margin
-234.27% +138.1pp
FY2025 Operating Margin FY2020–FY2025
Operating Cash Flow
-549.17M +18.6%
FY2025 Operating Cash Flow FY2020–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
SEK 222.27M 171.32M 134.09M 154.53M 33.88M 6.1M
SEK 83.56M 83.55M 63.14M 38.48M 15.43M 997K
SEK 304.74M 375.72M 411.33M 346.24M 230.76M 227.19M
SEK -520.71M -637.88M -788.5M -588.59M -546.98M -422.81M
SEK 122.49M 187.17M 105.52M 48.64M 1.22M 257K
SEK -531.84M -804.21M -830.81M -609.98M -548.13M -420.89M
SEK 2.27M 3.03M 908K 1.16M 152K -40K
SEK -534.11M -807.24M -831.72M -611.13M -548.28M -420.85M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current lease liabilities 2025-12-31 SEK 8,276,000 ESEF Annual Report filed 2026-03-26
Noncurrent lease liabilities 2025-12-31 SEK 2,995,000 ESEF Annual Report filed 2026-03-26
Noncurrent long-term borrowings 2025-12-31 SEK 790,534,000 ESEF Annual Report filed 2026-03-26
Short-term borrowings 2025-12-31 SEK 136,869,000 ESEF Annual Report filed 2026-03-26
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.